Seasoned Ophthalmology Executive Deb Jorn Joins PSivida To Focus On Corporate And Commercial Development

WATERTOWN, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, announced that Deb Jorn, a proven business development executive, has joined the Company as Executive Vice President of Corporate and Commercial Development, a newly created position reporting directly to Nancy Lurker, pSivida's President and Chief Executive Officer. Ms. Jorn's primary responsibilities will be to establish collaborations leveraging pSivida's unique technologies and finalizing an EU partnership deal for the Company's Durasert™ three-year uveitis, which was formerly known as Medidur.

Ms. Jorn's experience and expertise in corporate licensing, M&A and alliance management helped her build US and global pharmaceutical businesses across numerous therapeutic areas, including ophthalmology. Most recently, she was EVP and Company Chair at Valeant Pharmaceuticals and previously served as Chief Marketing Officer at Bausch & Lomb. Earlier, Ms. Jorn was Group VP of Womens' Healthcare and Fertility at Schering Plough. She was also at Johnson & Johnson as the Worldwide VP of Internal Medicine and Early Commercial Input. She began her career at Merck and for more than twenty years held roles of progressive responsibility in a variety of functions including R&D, regulatory, sales and marketing. Ms. Jorn holds a B.A. in Biochemistry from Rutgers University and an MBA from New York University's Stern Graduate School of Business Administration.

"Deb has an impressive track record and her knowledge of the ophthalmology market and her corporate licensing and M&A experience greatly enhance our team's capabilities," commented Ms. Lurker. "She is a proven leader who, in addition to her corporate licensing and M&A experience has also brought many iconic brands to market. I look forward to working with Deb as we begin the early planning for our future branding and launch of Durasert three-year uveitis in the EU and US."

If you liked this article you might like

Today's Weak On High Volume Stock: PSivida (PSDV)

Trade-Ideas: PSivida (PSDV) Is Today's Strong On High Relative Volume Stock

Psivida (PSDV) Upgraded From Sell to Hold

Why pSivida (PSDV) Stock Is Soaring in After-Hours Trading Today

3 Stocks Under $10 Moving Higher